The antimalarial compound fosmidomycin targets DXR, the enzyme that catalyzes the first committed step in the MEP pathway producing the essential isoprenoid precursors, isopentenyl diphosphate and dimethylallyl diphosphate. The MEP pathway is used by a number of pathogens, including Mycobacterium tuberculosis and apicomplexan parasites, and differs from the classical mevalonate pathway that is essential in humans. Using a structure-based approach, we designed a number of analogues of fosmidomycin, including a series that are substituted in both the Cα and the hydroxamate positions. The latter proved to be a stable framework for the design of inhibitors that extend from the polar and cramped (and so not easily druggable) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 substrate-binding site and can, for the first time, bridge the substrate and cofactor binding sites.
Introduction
Fosmidomycin (1) and its acetyl derivative, FR-900098 (2), are natural product antibiotics with activity against a number of important pathogens.
1,2 They work by blocking the pathway for biosynthesis of isopentenyl diphosphate and dimethylallyl diphosphate that proceeds via the although not all are sensitive to fosmidomycin and its analogues. For example, while both 1 and
We conclude that novel compounds need to be explored, and that existing compounds need to be tested against other organisms. Our structure-based approach to improving DXR inhibitors focused initially on modifying the 3,4-dichlorophenyl-substituted analogues in an attempt to utilize a conserved water-filled pocket we had earlier identified. However, this did not result in improved IC 50 values. 7 Here we describe a new strategy in which we extend from the hydroxamic acid group of fosmidomycin and related analogues. While we were still unsuccessful in terms of obtaining compounds active against M.
tuberculosis, some were highly active against P. falciparum growth in an in vitro blood cell spectrophotometric assay, in which the MtDXR-catalyzed NADPH-dependent rearrangement and reduction of DXP to form MEP was monitored at 340 nm.
Scheme 1. Synthesis of fosmidomycin analogues 8a-8j
a a Regents and conditions: i) 6a-6h, Acid chloride, DCM, rt; or 6i-6j, carboxylic acid, HATU/DIPEA, DMF, rt; ii) H 2 , 10% Pd/C, MeOH, rt; TMSBr, DCM, rt; iii) TMSBr, DCM, rt. Table 1 shows that none of these compounds inhibited MtDXR more effectively than fosmidomycin. The acetyl derivative, 2, showed a small drop in activity, 7, 10 which we attribute to minor changes in the interaction with the indole ring of Trp203 in the active site of MtDXR. In the first crystal structure of a DXR ternary complex in a conformational state suitable for catalysis, 10 we observed a well-defined active-site flap that covered the fosmidomycin bound in the substrate site. The relative orientation of the NADPH-binding domain suggested that the conformation would allow hydride transfer from the nicotinamide ring to the substrate. In this state, the indole ring of Trp203 from the flap forms a close set of interactions with the fosmidomycin backbone. The MtDXR-Mn-2-NADPH ternary complex showed a similar activesite structure and enzyme-inhibitor interactions, with the newly introduced methyl group of the 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This results from our choice of more stringent assay conditions, which should allow better discrimination among tight-binding compounds.
Unfortunately, none of these compounds had significant in vitro activity against M.
tuberculosis; they were not tested against P. falciparum.
The disubstituted fosmidomycin analogues. The approximate coplanarity of the hydroxamate and dichlorophenyl groups in the experimentally determined enzyme-inhibitor structures of 3 and 4 with MtDXR, 7 with both groups aimed out toward solvent, suggested that we could combine the Cα-substituent of 3 and the phenyl substituent of the hydroxamate in 8d to produce the disubstituted compound, 14a (Table 2 ). Compound 14a served as the lead for our second series, in which various substituents were added to the phenyl ring with the aim of reaching into the NADPH-binding site (see below). Groups were selected among commercially available acyl chlorides and carboxylic acids with a variety of size and other properties, guided by molecular modeling using the experimental MtDXR-Mn-14a structures (described below). This limited set of related analogues primarily investigated substitutions at the ortho position (see Table 2 ). All compounds were synthesized as racemic mixtures, as outlined in Scheme 2.
The key intermediate 11 was obtained in a previously reported, three-step synthetic route, 7, 24 starting with an oxidative Heck reaction between acrolein and 3,4-dichlorophenyl boronic acid, 30, 31 to furnish (E)-3-(3,4-dichlorophenyl)acrylaldehyde (9). This was followed by 1,4-addition of triethyl phosphate, and finally reductive amination with O-benzylhydroxylamine in the presence of sodium cyanoborohydride as reducing reagent, to produce 11. Depending on availability of starting materials, the next step was performed with acyl chlorides in DCM and triethylamine, furnishing compounds 12a -12d in 46-92% yield, or with suitable carboxylic acids using 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 propane phosphonic acid anhydride (T3P) in ethyl acetate as a coupling reagent (compounds 12f -12k, 43 -75% yields). The 2-(2-thienylmethyl)benzoic acid used to obtain compound 12e was prepared from 2-(2-thienylcarbonyl)benzoic acid by refluxing for 48 hours in ammonia with zinc powder. The benzyl protecting group in compounds 12a -12d and 12f -12k was removed via palladium-catalyzed (10% Pd/C) hydrogenation under atmospheric hydrogen pressure. Probably due to catalyst poisoning, the reaction did not give a product with the thiophene derivative (12e), even in harsher, acidic conditions. Debenzylation of 12e was easily achieved with trifluoroacetic acid (TFA), TMSBr and thioanisole. Final compounds were obtained by hydrolysis of the diethylphosphonates 13a -13k by TMSBr in DCM, and purified on reversed phase HPLC using gradient elution with acetonitrile in 0.1% aqueous TFA. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 acid, T3P, TEA, EtOAc, 0 °C then rt; v) H 2 , 10% Pd/C or TMSBr, TFA, thioanisole; vi) TMSBr, DCM, rt.
Biochemical/biological evaluation of the 14a series. Table 2 summarizes results for the compounds in the second series. The fact that these compounds were tested as racemic mixtures should be remembered in the interpretation of the data. While the crystallographic work (see below) indicates that the S-enantiomer is the predominant form bound to the enzyme, we have no proof at this time that activity of the R-enantiomer is entirely lacking. Therefore, the reported IC 50 s should be viewed as upper limits, with the true value probably closer to one half of this.
The lead compound 14a had submicromolar MtDXR activity (measured IC 50 =0.32 µM) and remarkably good in vitro growth inhibition in the P. falciparum parasite assay (IC 50 =0.04 µM).
Enzyme inhibition by this compound was less efficient than the Cα-substituted formyl derivative 3 but better than the acetyl derivative 4 ( Table 2 ). Introduction of progressively larger substituents at the ortho position of the phenyl ring resulted in a decline of MtDXR inhibitory activity. Surprisingly, all of the ortho-substituted compounds were inactive in the P. falciparum parasite growth assay. When the triazole substituent was moved from the ortho (14i) to the meta (14j) and para positions (14k), the MtDXR IC 50 -values were improved by 2 and 1 orders of magnitude, respectively. The activity in the P. falciparum parasite assay was also recovered in these two compounds. In fact, 14j had an MtDXR IC50-value that is comparable to 2. The best in vitro growth inhibition of P. falciparum, however, is shown by the lead compound, 14a (0.04 µM); it has five times the activity of 14k (0.19 µM), and ten times the activity of 14j (0.39 µM).
14a also has eight times the published activity of 2 (0.32 µM) 24 and at least an 8-fold improvement over fosmidomycin in our in vitro growth inhibition assays (fosmidomycin was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 used as a control in our assays, and had IC50-values in the range 0.2-0.4 µM, compared to values of 0.3-1.1 µM found in the literature).
6, 24
General comments on crystallographic results. Details of the crystallographic work are included in the Supplementary Information. All of the complexes represent monoclinic and tetragonal crystal forms that we have described previously, although there is a large variation in the unit cell constants for crystals of the monoclinic form. In the monoclinic crystals described here, as for most of our MtDXR structures, the asymmetric unit contains a complete dimer where the NADPH-binding site is more closed in one subunit (chain A; conformational state being described using a yardstick 10 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 inhibitor. 21 However, the flaps were not well ordered in the MtDXR-Mn-14a-NADPH complex studied here. Overall, therefore, the behavior of the active-site flap in structures of the complexes described in the present study was more similar to that seen in complexes with the dichlorophenyl Cα-substituted fosmidomycin analogues 3 and 4 than to the structures in complex with fosmidomycin or 2.
Mode of binding to 14a. We were able to crystallize 14a in complex with MtDXR in both of the known space groups, with and without the NADPH cofactor, and so can be certain that our conclusions are unbiased by any crystallographic artifacts. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 interacts with the side chain of Glu153, although the detailed sets of interactions differ. In the MtDXR-14i structure, a portion of the active-site flap in chain B is disordered (corresponding to residues A204-208), although it is ordered in the structure with 14f. Superposition of the same three structures was performed using the fosmidomycin backbone atoms, to highlight differences in the inhibitor conformation.
The ortho-substituted phenyl ring in both metal-free complexes (14f and 14i) makes intramolecular ring-ring interactions with the dichlorophenyl ring. In each case, the rings are closer to coplanarity than is observed in the MtDXR-Mn-14a complex (Figure 3b ). The ortho groups of the two compounds are directed towards, and entering, the NADPH-binding site. Both have an intramolecular contact to the para-chlorine atom (in the range 3.5-3.7 Å), but no intramolecular hydrogen-bonding interactions are observed. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Direct measurement of K D using fluorescence spectroscopy. As the structures of complexes with 14f and 14i showed that their ortho substituents impinge on the NADPH site, it seemed likely that the measured IC 50 would not be a good measure of ligand affinity, as discussed above for compound 8h. This led us to seek other methods for determining the affinity of MtDXR for the various compounds. A direct fluorescence assay, based on changes in the environment of one or more of the six tryptophan residues of the protein, proved a feasible option; the results with a number of compounds are presented in Table 3 . For five compounds (1, 3, 4, 14a, 14j) , the measured dissociation constant (K D ) in the presence of MnCl 2 agrees well with the degree of enzyme inhibition as indicated by the IC 50 s. The three compounds with ortho substitutions (14d, 14f, 14i) showed tighter binding than the unsubstituted lead (14a). The IC 50 s of these compounds, however, were much higher than their K D values (Table 2) , and so we conclude that, like 14f and 14i, other compounds with ortho substituents are likely to interfere with the binding of NADPH. The one para-substituted compound in the study, 14k, seems to have similar behavior, but more compounds will need to be synthesized and tested to determine if the effect is a general one.
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Structure-Activity Relationship (SAR) of analogues 14a-14k. None of the new compounds
inhibited the growth of M. tuberculosis strain H37Rv in a microplate Alamar blue assay (data not shown). In contrast, the disubstituted analogues (14a-14k) did show a range of activities against the P. falciparum 3D7 strain in an in vitro growth assay (Table 2) . Having obtained the crystal structures of three of the analogues in Table 2 , we could address the SAR of this set of compounds. The MtDXR inhibition of 14a is poorer than that of the formyl derivative 3, but better than the acetyl derivative 4 described earlier (Table 2) . 7 The structures of complexes with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 these three compounds (3, PDB entries 2Y1D and 2Y1F; 4, 2Y1G; 14a, 3ZHX and 3ZHY) all show a disordered active-site flap and otherwise share a great deal of similarity. In particular, the fosmidomycin backbone, dichlorophenyl ring and metal-ion coordination are highly conserved in these structures (Figure 2c ). Despite the poorer enzyme inhibition relative to 1, 2 and 3, the activity of 14a on P. falciparum growth is superior (40 nM, Table 2 ), and closely comparable to the reference compound artemisinin (IC 50 in the range 5-25 nM in our assays, similar to the value of 10 nM reported by Baniecki et al. cofactor. However, the high concentration of NADPH needed for the activity assay dictates that the IC 50 measurements for compounds entering the cofactor site will underestimate their actual binding constants. Our modeling of meta and para substitutions suggested that these would be easier to accommodate, which is borne out by the results with a limited number of modifications (involving a triazole ring) at each of the three positions (Table 2) . Although both 14j and 14k
show good inhibition of MtDXR activity and P. falciparum growth, neither improved on 14a.
Experimental Section
Chemistry. The microwave reactions were performed in a Smith Synthesizer producing MHz; the chemical shifts were referenced to 85% H 3 PO 4 which was used as an external standard.
Molecular masses (HR-ESI-MS) were determined on a Micromass Q-Tof2 mass spectrometer 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 equipped with an electrospray ion source. Compounds 9, 10 and 11 were synthesized as previously reported.
7, 24
Materials. Most reagents were purchased from commercial suppliers and used without further purification. DCM was distilled under nitrogen immediately before use; calcium hydride was used as a drying agent.
Diethyl-3-(N-(benzyloxy)phenylamido)-1-(3,4-dichlorophenyl)propylphosphonate (12a).
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